CGTG - Cancer Gene Therapy Group - University of Helsinki

CGTG Welcome Book

Everything a new (and also an old) CGTG group member needs to know.

click here to download

VIDEOS

Interview of Joao Dias: studying for a PhD at the University of Helsinki (language english)

High resolution, 10 min
Akseli Hemminki interviewed at DVD "Lääkärin työssä on sykettä" (language finnish)

High Resolution (Broadband, DSL); Low Resolution (Modem connections)

PUBLICATIONS - FOR PERSONAL USE OR TEACHING PURPOSES ONLY

Pesonen S, Diaconu I, Cerullo V, Escutenaire S, Raki M, Kangasniemi L, Nokisalmi P, Dotti G, Guse K, Laasonen L, Partanen K, Karli E, Haavisto E, Oksanen M, Karioja-Kallio A, Hannuksela P, Holm SL, Kauppinen S, Joensuu T, Kanerva A, Hemminki A.
Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.
Int J Cancer. 2011 May 31.[Epub ahead of print] click here to download
Wang H, Li Z, Yumul R, Lara S, Hemminki A, Fender P, Lieber A.
Multimerization of adenovirus serotype 3 fiber knob domains is required for efficient binding of virus to desmoglein 2 and subsequent opening of epithelial junctions.
J Virol. 2011 Apr 27. [Epub ahead of print] click here to download
Raki M, Sarkioja M, Escutenaire S, Kangasniemi L, Haavisto E, Kanerva A, Cerullo V, Joensuu T, Oksanen M, Pesonen S, Hemminki A.
Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients.
J Gene Med. 2011 Apr 25.[Epub ahead of print] click here to download
Rajecki M, Kangasmaki A, Laasonen L, Escutenaire S, Hakkarainen T, Haukka J, Ristimaki A, Kairemo K, Kangasniemi L, Kiljunen T, Joensuu T, Pesonen S, Hemminki A.
Sodium Iodide Symporter SPECT Imaging of a Patient Treated With Oncolytic Adenovirus Ad5/3-?24-hNIS
Mol Ther. 2011 Apr;19(4):629-31 click here to download
Guse K, Cerullo V & Hemminki A.
Oncolytic vaccinia virus for the treatment of cancer
Expert Opin Biol Ther. 2011 Feb 22. [Epub ahead of print]] click here to download
Strauss R, Li ZY, Liu Y, Beyer I, Persson J, Sova P, Moller T, Pesonen S, Hemminki A, Hamerlik P, Drescher C, Urban N, Bartek J, Lieber A.
Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity.
PLoS One. 2011 Feb 11;6(2). doi: 10.1371/annotation/8c637352-3614-406c-89dc-e78d10fa069c. click here to download
Escutenaire S, Cerullo V, Diaconu I, Ahtiainen L, Hannuksela P, Oksanen M, Haavisto E, Karioja-Kallio A, Holm SL, Kangasniemi L, Ribacka C, Kauppinen S, Joensuu T, Arstila TP, Pesonen S, Kanerva A, Hemminki A.
In vivo and in vitro distribution of type 5 and fiber-modified oncolytic adenoviruses in human blood compartments.
Ann Med. 2011 Mar;43(2):151-63 click here to download
Hemminki O, Bauerschmitz G, Hemmi S, Lavilla-Alonso S, Diaconu I, Guse K, Koski A, Desmond RA, Lappalainen M, Kanerva A, Cerullo V, Pesonen S, Hemminki A.
Oncolytic adenovirus based on serotype 3.
Cancer Gene Ther. 2010 Dec 24. [Epub ahead of print] click here to download
Kim KH, Ryan MJ, Estep JE, Miniard BM, Rudge TL, Peggins JO, Broadt TL, Wang M, Preuss M, Siegal GP, Hemminki A, Harris RD, Aurigemma R, Curiel D, Alvarez RD.
A New Generation of Serotype Chimeric Infectivity-Enhanced CRAds: The Safety Profile of Ad5/3-?24 in Advance of a Phase I Clinical Trial in Ovarian Cancer Patients.
Hum Gene Ther. 2010 Dec 20. [Epub ahead of print] click here to download
Wang H, Li ZY, Liu Y, Persson J, Beyer I, Moller T, Koyuncu D, Drescher MR, Strauss R, Zhang XB, Wahl JK 3rd, Urban N, Drescher C, Hemminki A, Fender P, Lieber A.
Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14.
Nat Med. 2011 Jan;17(1):96-104 click here to download
Pesonen S, Kangasniemi L, Hemminki A.
Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data.
Mol Pharm. 2010 Dec 2. [Epub ahead of print] click here to download
Ahtiainen L, Mirantes C, Jahkola T, Escutenaire S, Diaconu I, Osterlund P, Kanerva A, Cerullo V, Hemminki A.
Defects in innate immunity render breast cancer initiating cells permissive to oncolytic adenovirus.
PLoS One. 2010 Nov 5;5(11):e13859. click here to download
Rajecki M, Raki M, Escutenaire S, Pesonen S, Cerullo V, Helminen A, Hannuksela P, Partanen K, Laasonen L, Joensuu T, Kangasniemi L, Haavisto E, Kanerva A, Ahtiainen L, Hemminki A.
Safety of Glucocorticoids in Cancer Patients Treated with Oncolytic Adenoviruses
Mol Pharm. 2010 Nov 8. [Epub ahead of print] click here to download
Ahonen MT, Diaconu I, Pesonen S, Kanerva A, Baumann M, Parviainen ST, Spiller B, Cerullo V, Hemminki A
Calcium gluconate in phosphate buffered saline increases gene delivery with adenovirus type 5
PLoS One. 2010 Sep 30;5(9). pii: e13103 click here to download
Liikanen I, Dias JD, Nokisalmi P, Sloniecka M, Kangasniemi L, Rajecki M, Dobner T, Tenhunen M, Kanerva A, Pesonen S, Ahtiainen L, Hemminki A.
Adenoviral E4orf3 and E4orf6 proteins, but not E1B55K, increase killing of cancer cells by radiotherapy in vivo
Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1201-9. click here to download
Lavilla-Alonso S, Bauerschmitz G, Abo-Ramadan U, Halavaara J, Escutenaire S, Diaconu I, Tatlisumak T, Kanerva A, Hemminki A, Pesonen S
Adenoviruses with an avb integrin targeting moiety in the fiber shaft or the HI-loop increase tumor specificity without compromising antitumor efficacy in magnetic resonance imaging of colorectal cancer metastases
J Transl Med. 2010 Aug 23;8:80 click here to download
Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo V, Diaconu I, Nokisalmi P, Raki M, Rajecki M, Guse K, Ranki T, Oksanen M, Holm SL, Haavisto E, Karioja-Kallio A, Laasonen L, Partanen K, Ugolini M, Helminen A, Karli E, Hannuksela P, Pesonen S, Joensuu T, Kanerva A, Hemminki A.
Treatment of Cancer Patients With a Serotype 5/3 Chimeric Oncolytic Adenovirus Expressing GMCSF
Mol Ther. 2010;18:1874-84. click here to download
Tyynismaa H, Carroll CJ, Raimundo N, Ahola-Erkkilä S, Wenz T, Ruhanen H, Guse K, Hemminki A, Peltola-Mjøsund KE, Tulkki V, Oresic M, Moraes CT, Pietiläinen K, Hovatta I, Suomalainen A.
Mitochondrial myopathy induces a starvation-like response
Hum Mol Genet. 2010;19:3948-58. click here to download
Nokisalmi P, Pesonen S, Escutenaire S, Särkioja M, Raki M, Cerullo V, Laasonen L, Alemany R, Rojas J, Cascallo M, Guse K, Rajecki M, Kangasniemi L, Haavisto E, Karioja-Kallio A, Hannuksela P, Oksanen M, Kanerva A, Joensuu T, Ahtiainen L, Hemminki A.
Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors.
Clin Cancer Res. 2010 Jun 1;16(11):3035-43. click here to download
Cerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila PT, Ugolini M, Nokisalmi P, Raki M, Laasonen L, Särkioja M, Rajecki M, Kangasniemi L, Guse K, Helminen A, Ahtiainen L, Ristimäki A, Räisänen-Sokolowski A, Haavisto E, Oksanen M, Karli E, Karioja-Kallio A, Holm SL, Kouri M, Joensuu T, Kanerva A, Hemminki A.
Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients.
Cancer Res. 2010 Jun 1;70(11):4297-309. click here to download
Diaconu I, Cerullo V, Escutenaire S, Kanerva A, Bauerschmitz GJ, Hernandez-Alcoceba R, Pesonen S, Hemminki A.
Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir.
J Gene Med. 2010 May;12(5):435-45. click here to download
Dias JD, Liikanen I, Guse K, Foloppe J, Sloniecka M, Diaconu I, Rantanen V, Eriksson M, Hakkarainen T, Lusky M, Erbs P, Escutenaire S, Kanerva A, Pesonen S, Cerullo V, Hemminki A.
Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1.
Clin Cancer Res. 2010 May 1;16(9):2540-9. click here to download
Pesonen S, Nokisalmi P, Escutenaire S, Särkioja M, Raki M, Cerullo V, Kangasniemi L, Laasonen L, Ribacka C, Guse K, Haavisto E, Oksanen M, Rajecki M, Helminen A, Ristimäki A, Karioja-Kallio A, Karli E, Kantola T, Bauerschmitz G, Kanerva A, Joensuu T, Hemminki A.
Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors.
Gene Ther. 2010;17(7):892-904. click here to download
Guse K, Hemminki A.
Cancer gene therapy with oncolytic adenoviruses.
J BUON. 2009 Sep;14 Suppl 1:S7-15. click here to download
Dias JD, Guse K, Nokisalmi P, Eriksson M, Chen DT, Diaconu I, Tenhunen M, Liikanen I, Grénman R, Savontaus M, Pesonen S, Cerullo V, Hemminki A.
Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage tumour cell cultures.
Eur J Cancer. 2010; 46:625-35. click here to download
Joensuu G, Joensuu T, Nokisalmi P, Reddy C, Isola J, Ruutu M, Kouri M, Kupelian PA, Collan J, Pesonen S, Hemminki A.
A Phase I/II Trial of Gefitinib Given Concurrently with Radiotherapy in Patients with Nonmetastatic Prostate Cancer.
Int J Radiat Oncol Biol Phys. 2010;78(1):42-9. click here to download
Wang H, Liu Y, Li ZY, Fan X, Hemminki A, Lieber A.
A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy.
Blood. 2010 Jan 21;115(3):592-600. click here to download
Guse K, Sloniecka M, Diaconu I, Ottolino-Perry K, Tang N, Ng C, Le Boeuf F, Bell JC, McCart JA, Ristimäki A, Pesonen S, Cerullo V, Hemminki A.
Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models.
J Virol. 2010;84(2):856-66 click here to download
Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Asola R, Kokko R, Ahlgren J, Auvinen P, Hemminki A, Paija O, Helle L, Nuortio L, Villman K, Nilsson G, Lahtela SL, Lehtiö K, Pajunen M, Poikonen P, Nyandoto P, Kataja V, Bono P, Leinonen M, Lindman H; on behalf of the FinXX Study Investigators
Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial.
Lancet Oncol. 2009 Dec;10(12):1145-51 click here to download
Pesonen S, Helin H, Nokisalmi P, Escutenaire S, Ribacka C, Sarkioja M, Cerullo V, Guse K, Bauerschmitz G, Laasonen L, Kantola T, Ristimaki A, Rajecki M, Oksanen M, Haavisto E, Kanerva A, Joensuu T, Hemminki A.
Oncolytic adenovirus treatment of a patient with refractory neuroblastoma.
Acta Oncol. 2010; 49:117-9. click here to download
Rojas JJ, Cascallo M, Guedan S, Gros A, Martinez-Quintanilla J, Hemminki A, Alemany R
A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses.
Gene Ther. 2009;16:1441-51. click here to download
Hakkarainen T, Rajecki M, Sarparanta M, Tenhunen M, Airaksinen AJ, Desmond RA, Kairemo K, Hemminki A.
Targeted radiotherapy for prostate cancer with an oncolytic adenovirus coding for human sodium iodide symporter.
Clin Cancer Res. 2009 Sep 1;15(17):5396-403. click here to download
Rajecki M, Hällström TA, Hakkarainen T, Nokisalmi P, Hautaniemi S, Nieminen AI, Tenhunen M, Rantanen V, Desmond RA, Chen DT, Guse K, Stenman UH, Gargini R, Kapanen M, Klefström J, Kanerva A, Pesonen S, Ahtiainen L, Hemminki A.
Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiation.
Int J Cancer. 2009;125:2441-9. click here to download
Koski A, Rajecki M, Guse K, Kanerva A, Ristimäki A, Pesonen S, Escutenaire S, Hemminki A.
Systemic adenoviral gene delivery to orthotopic murine breast tumors with ablation of coagulation factors, thrombocytes and Kupffer cells.
J Gene Med. 2009;11:966-77. click here to download
Bayo-Puxan N, Gimenez-Alejandre M, Lavilla-Alonso S, Gros A, Cascallo M, Hemminki A, Alemany R.
Replacement of Adenovirus Type 5 Fiber Shaft Heparan Sulfate Proteoglycan-Binding Domain with RGD for Improved Tumor Infectivity and Targeting.
Hum Gene Ther. 2009;20:1214-21 click here to download
Matthews K, Noker PE, Tian B, Grimes SD, Fulton R, Schweikart K, Harris R, Aurigemma R, Wang M, Barnes MN, Siegal GP, Hemminki A, Zinn K, Curiel DT, Alvarez RD
Identifying the safety profile of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in anticipation of a phase I clinical trial in patients with recurrent ovarian cancer.
Clin Cancer Res. 2009 Jun 15;15(12):4131-7. click here to download
Strauss R, Sova P, Liu Y, Li ZY, Tuve S, Pritchard D, Brinkkoetter P, Möller T, Wildner O, Pesonen S, Hemminki A, Urban N, Drescher C, Lieber A
Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses.
Cancer Res. 2009 Jun 15;69(12):5115-25. click here to download
Guse K, Diaconu I, Rajecki M, Sloniecka M, Hakkarainen T, Ristimäki A, Kanerva A, Pesonen S, Hemminki A.
Ad5/3-9HIF-Delta24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment.
Gene Ther. 2009 Aug;16(8):1009-20. click here to download
Diaconu I, Denby L, Pesonen S, Cerullo V, Bauerschmitz GJ, Guse K, Rajecki M, Dias JD, Taari K, Kanerva A, Baker A, Hemminki A.
Serotype chimeric and fiber mutated adenovirus Ad5/19p-HIT for targeting renal cancer and untargeting the liver.
Hum Gene Ther. 2009 Jun;20(6):611-20. click here to download
Ylösmäki E, Hakkarainen T, Hemminki A, Visakorpi T, Andino R, Saksela K.
Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA.
J Virol. 2008 Nov;82(22):11009-15. click here to download
Kangasniemi L, Koskinen M, Jokinen M, Toriseva M, Ala-Aho R, Kähäri VM, Jalonen H, Ylä-Herttuala S, Moilanen H, Stenman UH, Diaconu I, Kanerva A, Pesonen S, Hakkarainen T, Hemminki A.
Extended release of adenovirus from silica implants in vitro and in vivo.
Gene Ther. 2009 Jan;16(1):103-10. click here to download
Rajecki M, Joensuu T, Hemminki A.
Oncolytic adenoviruses for the treatment of cancer – a clinical perspective
Lääkärilehti 2008; 38:3085-3093 Review. Finnish. click here to download
Kanerva A, Lavilla-Alonso S, Raki M, Kangasniemi L, Bauerschmitz GJ, Takayama K, Ristimäki A, Desmond RA, Hemminki A.
Systemic therapy for cervical cancer with potentially regulatable oncolytic adenoviruses.
PLoS ONE. 2008 Aug 13;3(8):e2917. click here to download
Bauerschmitz GJ, Ranki T, Kangasniemi L, Ribacka C, Eriksson M, Porten M, Herrmann I, Ristimäki A, Virkkunen P, Tarkkanen M, Hakkarainen T, Kanerva A, Rein D, Pesonen S, Hemminki A.
Tissue-specific promoters active in CD44+CD24-/low breast cancer cells.
Cancer Res. 2008 Jul 15;68(14):5533-9. click here to download
Ribacka C, Pesonen S, Hemminki A.
Cancer, stem cells, and oncolytic viruses.
Ann Med. 2008;40:496-505. click here to download
Särkioja M, Pesonen S, Raki M, Hakkarainen T, Salo J, Ahonen MT, Kanerva A, Hemminki A.
Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies.
Gene Ther. 2008 Jun;15(12):921-9. click here to download
Ribacka C, Hemminki A.
Virotherapy as an approach against cancer stem cells.
Curr Gene Ther. 2008 Apr;8(2):88-96. click here to download
Särkioja M, Hakkarainen T, Eriksson M, Ristimäki A, Desmond RA, Kanerva A, Hemminki A.
The cyclo-oxygenase 2 promoter is induced in nontarget cells following adenovirus infection, but an AU-rich 3'-untranslated region destabilization element can increase specificity.
J Gene Med. 2008;10:744-53. click here to download
Raki M, Sarkioja M, Desmond RA, Chen DT, Butzow R, Hemminki A, Kanerva A.
Oncolytic adenovirus Ad5/3-Delta24 and chemotherapy for treatment of orthotopic ovarian cancer.
Gynecol Oncol. 2008;108:166-72 click here to download
Guse K, Ranki T, Ala-Opas M, Bono P, Sarkioja M, Rajecki M, Kanerva A, Hakkarainen T, Hemminki A.
Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses.
Mol Cancer Ther. 2007 Oct;6(10):2728-36. click here to download
Eriksson M, Guse K, Bauerschmitz G, Virkkunen P, Tarkkanen M, Tanner M, Hakkarainen T, Kanerva A, Desmond RA, Pesonen S, Hemminki A.
Oncolytic Adenoviruses Kill Breast Cancer Initiating CD44(+)CD24(-/Low) Cells.
Mol Ther. 2007 Dec;15(12):2088-93. click here to download
Kanerva A, Raki M, Hemminki A.
Gene therapy of gynaecological diseases.
Expert Opin Biol Ther. 2007 Sep;7(9):1347-61. Review. click here to download
Raki M, Hakkarainen T, Bauerschmitz GJ, Sarkioja M, Desmond RA, Kanerva A, Hemminki A.
Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus.
Gene Ther. 2007 Oct;14(19):1380-1388. click here to download
Hakkarainen T, Sarkioja M, Lehenkari P, Miettinen S, Ylikomi T, Suuronen R, Desmond RA, Kanerva A, Hemminki A.
Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors.
Hum Gene Ther. 2007 Jul;18(7):627-41. click here to download
Ranki T, Sarkioja M, Hakkarainen T, Smitten K, Kanerva A, Hemminki A.
Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer.
Int J Cancer. 2007 Jul 1;121(1):2919-28. click here to download
Guse K, Dias JD, Bauerschmitz GJ, Hakkarainen T, Aavik E, Ranki T, Pisto T, Sarkioja M, Desmond RA, Kanerva A, Hemminki A
Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo
Gene Ther. 2007 Jun;14(11):902-11. click here to download
Rajecki M, Kanerva A, Stenman UH, Tenhunen M, Kangasniemi L, Särkioja M, Ala-Opas MY, Alfthan H, Sankila A, Rintala E, Desmond RA, Hakkarainen T, Hemminki A
Treatment of prostate cancer with Ad5/3Delta24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo
Mol Cancer Ther. 2007 Feb;6(2):742-51. click here to download
Lam JT, Hemminki A, Kanerva A, Lee KB, Blackwell JL, Desmond R, Siegal GP, Curiel DT
A three-dimensional assay for measurement of viral-induced oncolysis
Cancer Gene Ther. 2007 Apr;14(4):421-30. click here to download
Kanerva A, Raki M, Ranki T, Sarkioja M, Koponen J, Desmond RA, Helin A, Stenman UH, Isoniemi H, Hockerstedt K, Ristimaki A, Hemminki A
Chlorpromazine and apigenin reduce adenovirus replication and decrease replication associated toxicity
J Gene Med. 2007 Jan;9(1):3-9. click here to download
Ranki T, Kanerva A, Ristimaki A, Hakkarainen T, Sarkioja M, Kangasniemi L, Raki M, Laakkonen P, Goodison S, Hemminki A
A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer
Gene Ther. 2007 Jan;14(1):58-67. click here to download
Shi W, Hemminki A, Bartlett JS
Capsid modifications overcome low heterogeneous expression of heparan sulfate proteoglycan that limits AAV2-mediated gene transfer and therapeutic efficacy in human ovarian carcinoma
Gynecol Oncol. 2006 Dec;103(3):1054-62. click here to download
Sarkioja M, Kanerva A, Salo J, Kangasniemi L, Eriksson M, Raki M, Ranki T, Hakkarainen T, Hemminki A
Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenoviruses in an orthotopic model of advanced lung cancer
Cancer. 2006 Oct 1;107(7):1578-88. click here to download
Raki M, Rein DT, Kanerva A, Hemminki A
Gene transfer approaches for gynecological diseases
Mol Ther. 2006 Aug;14(2):154-63. click here to download
Bauerschmitz GJ, Guse K, Kanerva A, Menzel A, Herrmann I, Desmond RA, Yamamoto M, Nettelbeck DM, Hakkarainen T, Dall P, Curiel DT, Hemminki A
Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells
Mol Ther. 2006 Aug;14(2):164-74. click here to download
Kangasniemi L, Kiviluoto T, Kanerva A, Raki M, Ranki T, Sarkioja M, Wu H, Marini F, Hockerstedt K, Isoniemi H, Alfthan H, Stenman UH, Curiel DT, Hemminki A
Infectivity-enhanced adenoviruses deliver efficacy in clinical samples and orthotopic models of disseminated gastric cancer
Clin Cancer Res. 2006 May 15;12(10):3137-44. click here to download
Hemminki A, Kellokumpu-Lehtinen PL.
Harmful impact of EU clinical trials directive.
BMJ. 2006 Mar 4;332(7540):501-2. click here to download
Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkio S, Flander M, Helle L, Ingalsuo S, Johansson K, Jaaskelainen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J; FinHer Study Investigators.
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
N Engl J Med. 2006 Feb 23;354(8):809-20. click here to download
Hemminki A.
Mitä tapahtui kliiniselle syöpälääketutkimukselle?
SUOMEN LÄÄKÄRILEHTI 48/2005 VSK 60. [FINNISH] click here to download
Raki M, Kanerva A, Ristimaki A, Desmond RA, Chen DT, Ranki T, Sarkioja M, Kangasniemi L, Hemminki A.
Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer.
Gene Ther. 2005 Aug;12(15):1198-205. click here to download
Arango D, Laiho P, Kokko A, Alhopuro P, Sammalkorpi H, Salovaara R, Nicorici D, Hautaniemi S, Alazzouzi H, Mecklin JP, Jarvinen H, Hemminki A, Astola J, Schwartz S Jr, Aaltonen LA
Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer
Gastroenterology. 2005 Sep;129(3):874-84. click here to download
Hakkarainen T, Wahlfors T, Merilainen O, Loimas S, Hemminki A, Wahlfors J.
VP22 does not significantly enhance enzyme prodrug cancer gene therapy as a part of a VP22-HSVTk-GFP triple fusion construct
J Gene Med. 2005 Jul;7(7):898-907. click here to download
Kanerva A, Zinn KR, Peng KW, Ranki T, Kangasniemi L, Chaudhuri TR, Desmond RA, Wang M, Takayama K, Hakkarainen T, Alfthan H, Stenman UH, Curiel DT, Hemminki A
Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus
Gene Ther. 2005 Jan;12(1):87-94. click here to download
Hakkarainen T, Kanerva A, Hemminki A
[Adenoviruses in cancer therapy] Adenovirukset syövän hoidossa
Duodecim. 2005;121(20):2195-203. Review. Finnish. click here to download
Kanerva A, Hemminki A
Adenoviruses for treatment of cancer
Ann Med. 2005;37(1):33-43. Review. click here to download
Lam JT, Kanerva A, Bauerschmitz GJ, Takayama K, Suzuki K, Yamamoto M, Bhoola SM, Liu B, Wang M, Barnes MN, Alvarez RD, Siegal GP, Curiel DT, Hemminki A
Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy
J Gene Med. 2004 Dec;6(12):1333-42. click here to download
Bauerschmitz GJ, Kanerva A, Wang M, Herrmann I, Shaw DR, Strong TV, Desmond R, Rein DT, Dall P, Curiel DT, Hemminki A
Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer
Int J Cancer. 2004 Aug 20;111(2):303-9. click here to download
Kanerva A, Hemminki A
Modified adenoviruses for cancer gene therapy
Int J Cancer. 2004 Jul 1;110(4):475-80. Review. click here to download
Kanerva A, Bauerschmitz GJ, Yamamoto M, Lam JT, Alvarez RD, Siegal GP, Curiel DT, Hemminki A
A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma
Gene Ther. 2004 Mar;11(6):552-9. click here to download
Kanerva A, Hemminki A
Replication component viruses for cancer therapy
Drugs of the Future 2004, 29(4). click here to download
Volk AL, Rivera AA, Kanerva A, Bauerschmitz G, Dmitriev I, Nettelbeck DM, Curiel DT
Enhanced adenovirus infection of melanoma cells by fiber-modification: incorporation of RGD peptide or Ad5/3 chimerism
Cancer Biol Ther. 2003 Sep-Oct;2(5):511-5. click here to download
Kanerva A, Zinn KR, Chaudhuri TR, Lam JT, Suzuki K, Uil TG, Hakkarainen T, Bauerschmitz GJ, Wang M, Liu B, Cao Z, Alvarez RD, Curiel DT, Hemminki A
Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus
Mol Ther. 2003 Sep;8(3):449-58. click here to download
Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, David O, Burow M, Gordon A, Dhurandhar N, Myers L, Berggren R, Hemminki A, Alvarez RD, Emilie D, Curiel DT, Chen L, Zou W
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
2003 May;9(5):562-7. click here to download
Barker SD, Coolidge CJ, Kanerva A, Hakkarainen T, Yamamoto M, Liu B, Rivera AA, Bhoola SM, Barnes MN, Alvarez RD, Curiel DT, Hemminki A
The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy
J Gene Med. 2003 Apr;5(4):300-10. click here to download
Hakkarainen T, Hemminki A, Pereboev AV, Barker SD, Asiedu CK, Strong TV, Kanerva A, Wahlfors J, Curiel DT
CD40 is expressed on ovarian cancer cells and can be utilized for targeting adenoviruses
Clin Cancer Res. 2003 Feb;9(2):619-24. click here to download
Hemminki A, Kanerva A, Kremer EJ, Bauerschmitz GJ, Smith BF, Liu B, Wang M, Desmond RA, Keriel A, Barnett B, Baker HJ, Siegal GP, Curiel DT
A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model
Mol Ther. 2003 Feb;7(2):163-73. click here to download
Hemminki A, Kanerva A, Liu B, Wang M, Alvarez RD, Siegal GP, Curiel DT
Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression
Cancer Res. 2003 Feb 15;63(4):847-53. click here to download
Bauerschmitz GJ, Barker SD, Hemminki A
Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review)
Int J Oncol. 2002 Dec;21(6):1161-74. Review. click here to download
Hemminki A, Wang M, Desmond RA, Strong TV, Alvarez RD, Curiel DT
Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy
Hum Gene Ther. 2002 Aug 10;13(12):1505-14. click here to download
Haviv YS, Blackwell JL, Kanerva A, Nagi P, Krasnykh V, Dmitriev I, Wang M, Naito S, Lei X, Hemminki A, Carey D, Curiel DT
Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors
Cancer Res. 2002 Aug 1;62(15):4273-81. click here to download
Kanerva A, Wang M, Bauerschmitz GJ, Lam JT, Desmond RA, Bhoola SM, Barnes MN, Alvarez RD, Siegal GP, Curiel DT, Hemminki A
Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses
Mol Ther. 2002 Jun;5(6):695-704. click here to download
Hemminki A, Zinn KR, Liu B, Chaudhuri TR, Desmond RA, Rogers BE, Barnes MN, Alvarez RD, Curiel DT
In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus
J Natl Cancer Inst. 2002 May 15;94(10):741-9. click here to download
Bauerschmitz GJ, Lam JT, Kanerva A, Suzuki K, Nettelbeck DM, Dmitriev I, Krasnykh V, Mikheeva GV, Barnes MN, Alvarez RD, Dall P, Alemany R, Curiel DT, Hemminki A
Treatment of ovarian cancer with a tropism modified oncolytic adenovirus
Cancer Res. 2002 Mar 1;62(5):1266-70. click here to download
Hemminki A
From molecular changes to customised therapy
Eur J Cancer. 2002 Feb;38(3):333-8. Review. click here to download
Kanerva A, Mikheeva GV, Krasnykh V, Coolidge CJ, Lam JT, Mahasreshti PJ, Barker SD, Straughn M, Barnes MN, Alvarez RD, Hemminki A, Curiel DT
Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells
Clin Cancer Res. 2002 Jan;8(1):275-80. click here to download
Hemminki A, Alvarez RD
Adenoviruses in oncology: a viable option?
BioDrugs. 2002;16(2):77-87. Review. click here to download
Hemminki A
Geeniterapia kohdentamaan solunsalpaajahoitoa munasarjasyövässä
Duodecim 2002;118:1100–2. [FINNISH] click here to download
Hemminki A, Dmitriev I, Liu B, Desmond RA, Alemany R, Curiel DT.
Targeting oncolytic adenoviral agents to the epidermal growth factor pathway with a secretory fusion molecule
Cancer Res. 2001 Sep 1;61(17):6377-81. click here to download
Hemminki A, Belousova N, Zinn KR, Liu B, Wang M, Chaudhuri TR, Rogers BE, Buchsbaum DJ, Siegal GP, Barnes MN, Gomez-Navarro J, Curiel DT, Alvarez RD.
An adenovirus with enhanced infectivity mediates molecular chemotherapy of ovarian cancer cells and allows imaging of gene expression
Mol Ther. 2001 Sep;4(3):223-31. click here to download
Casado E, Nettelbeck DM, Gomez-Navarro J, Hemminki A, Gonzalez Baron M, Siegal GP, Barnes MN, Alvarez RD, Curiel DT
Transcriptional targeting for ovarian cancer gene therapy
Gynecol Oncol. 2001 Aug;82(2):229-37. Review. click here to download
Casado E, Gomez-Navarro J, Yamamoto M, Adachi Y, Coolidge CJ, Arafat WO, Barker SD, Wang MH, Mahasreshti PJ, Hemminki A, Gonzalez-Baron M, Barnes MN, Pustilnik TB, Siegal GP, Alvarez RD, Curiel DT
Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications
Clin Cancer Res. 2001 Aug;7(8):2496-504. click here to download
Hemminki A, Joensuu H
Reply to comment on: Microsatellite Instability as a Molecular Marker for Very Good Survival in Colorectal Cancer Patients Receiving Adjuvant Chemotherapy
Gastroenterology. 2001 Apr;120(5):1309-10. click here to download
Hemminki A, Mecklin JP, Jarvinen H, Aaltonen LA, Joensuu H
Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy
Gastroenterology. 2000 Oct;119(4):921-8. click here to download
Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, Bignell G, Warren W, Aminoff M, Hoglund P, Jarvinen H, Kristo P, Pelin K, Ridanpaa M, Salovaara R, Toro T, Bodmer W, Olschwang S, Olsen AS, Stratton MR, de la Chapelle A, Aaltonen LA
A serine/threonine kinase gene defective in Peutz-Jeghers syndrome
Nature. 1998 Jan 8;391(6663):184-7. click here to download